NEW YORK, May 11, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences, you are encouraged to obtain additional information by contacting Ross Shikowitz at ross@bfalaw.com, calling us at 212-789-3619, or by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
There is no cost to you.
Why is Ventyx Being Investigated by BFA?
Directors and officers of a company owe fiduciary duties to the corporation and its stockholders. Bleichmar Fonti & Auld is investigating whether Ventyx’s Directors breached these fiduciary duties and/or engaged in other securities law violations.
What Can You Do?
If you are a shareholder of Ventyx Biosciences, Inc. you may have legal options. All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.
To obtain more information please contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder derivative litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.
